{
    "nct_id": "NCT04009668",
    "official_title": "Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease",
    "inclusion_criteria": "* Kidney biopsy confirmed Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)\n* For Minimal Change Disease patients only, history of resistance to corticosteroid therapy\n* Increased urinary excretion of biomarkers of Tumor Necrosis Factor (TNF) activation (MCP1/Cr and/ or TIMP1/Cr) at study screening\n* eGFR>30 ml/min/1.73 m2 at screening\n* Urine protein:creatinine ratio â‰¥1.5 g/g at screening\n* Weight >15 kg\n* Stable therapy with angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and oral immunosuppression agents for at least 30 days prior to enrollment\n* Birth control use in females of child bearing potential\n* Informed consent and assent if applicable\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Kidney or other solid organ or bone marrow transplant recipient\n* Allergy or intolerance to investigational agent\n* Secondary Focal Segmental Glomerulosclerosis (FSGS)\n* Severe obesity\n* Live virus vaccine in the past 3 months\n* Malignancy, current or in the past 5 years\n* Active local or systemic bacterial, fungal or viral infection\n* Active or latent Hepatitis B, Hepatitis C, HIV, or tuberculosis\n* History of demyelinating disease, e.g. Multiple Sclerosis or Guillain-Barre\n* History of heart failure\n* Active liver disease\n* Systemic lupus erythematosus or ANA > 1:80\n* History of inflammatory bowel disease, e.g. ulcerative colitis or Crohns disease\n* Cyclophosphamide in past 90 days, Rituximab in the past 180 days\n* Pregnancy or nursing\n* Blood white blood cell count <4,500/mm3; Hg <9 g/dL; Platelet count <150,000/mm3 at enrollment. - Use of an erythropoiesis stimulating agent will not be an exclusion criterion.\n* Concurrent use of interleukin-1 antagonist (Anakinra), other TNF blocking agent, methotrexate or abatacept\n* Diabetes Mellitus",
    "miscellaneous_criteria": ""
}